SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-066008
Filing Date
2022-05-27
Accepted
2022-05-27 17:03:11
Documents
12
Period of Report
2022-05-27
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2216951-2_8k.htm   iXBRL 8-K 26285
  Complete submission text file 0001104659-22-066008.txt   199303

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fwbi-20220527.xsd EX-101.SCH 3045
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fwbi-20220527_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fwbi-20220527_pre.xml EX-101.PRE 22603
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2216951-2_8k_htm.xml XML 3608
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
First Wave BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 464993860 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 22978747
SIC: 2834 Pharmaceutical Preparations